Consistently, the samples from in vivo assay also showed that the protein expression of p-AKT, p-GSK-3β, β-catenin, and Bcl-2 significantly decreased (p < 0.01, p < 0.001), while the level of cleaved caspase-3 and Bax increased in the ZSD and HSOL treatment groups compared with the model group (p < 0.05, p < 0.01; Figure 6(b)). The gene discussed is GSK3B; the disease is peroxisome biogenesis disorder.